دورية أكاديمية
Use of oral rivaroxaban in cerebral venous thrombosis.
| العنوان: | Use of oral rivaroxaban in cerebral venous thrombosis. |
|---|---|
| المؤلفون: | Maqsood M; Department of Medicine, Lahore General Hospital, Lahore, Pakistan., Imran Hasan Khan M; Department of Medicine, Lahore General Hospital, Lahore, Pakistan., Yameen M; Department of Pathology, Rawalpindi Medical College, Rawalpindi, Pakistan., Aziz Ahmed K; Department of Medicine, Lahore General Hospital, Lahore, Pakistan., Hussain N; Centre for Applied Molecular Biology (CAMB), University of the Punjab, Lahore, Pakistan., Hussain S; Centre for Applied Molecular Biology (CAMB), University of the Punjab, Lahore, Pakistan. |
| المصدر: | Journal of drug assessment [J Drug Assess] 2020 Dec 02; Vol. 10 (1), pp. 1-6. Date of Electronic Publication: 2020 Dec 02. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101672979 Publication Model: Electronic Cited Medium: Print ISSN: 2155-6660 (Print) Linking ISSN: 21556660 NLM ISO Abbreviation: J Drug Assess Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: <2015-2023> : Abingdon : Taylor & Francis Original Publication: 2011- : London, U.K. : Informa Healthcare |
| مستخلص: | Background: Cerebral venous thrombosis (CVT) is an uncommon cause of stroke in humans and the mainstay of treatment is anticoagulation unless contraindicated. Non-vitamin K oral anticoagulants have not been duly evaluated in randomized controlled trials in CVT. Objective: To compare the efficacy and safety of oral rivaroxaban with vitamin K anticoagulant (warfarin) in preventing recurrent venous thromboembolism (VTE) in patients with CVT. Methods: Adult patients with CVT, who were stable after 5-12 days of treatment with parenteral heparin 1 mg/kg, were screened for eligibility. The patients were randomly divided into two groups to receive oral rivaroxaban 20-30 mg daily or warfarin 1, 3 or 5 mg daily (with the dose adjusted to maintain an INR of 2-3), for 3-12 months. Recanalization rates, periprocedural complications, and clinical outcomes were assessed by Magnetic Resonance Venography (MRV) and National Institutes of Health Stroke Scale (NIHSS) at 3rd, 6th and 12th month follow-ups. Results: In total, 45 patients with CVT were randomized to the two treatment groups (21 to rivaroxaban and 24 to warfarin). Overall recanalization was achieved by 18 (86%) and 20 (83%) cases from rivaroxaban and warfarin group, respectively at 6th month follow-up; and by all 45 (100%) cases from the both groups at 12th month follow-up. Excellent outcome (NIHSS score 0) was obtained by 20 (95%) cases from rivaroxaban group at 3rd to 12th month follow-ups; and by 23 (96%) cases at 6th to 12th month follow-ups. There were no major bleeding events during the trial. None of the patients developed recurrence of thrombosis. Statistically, no significant difference between the two treatment groups in terms of recanalization and clinical outcomes could be observed. Conclusion: Rivaroxaban is a safe option in CVT however; larger randomized controlled studies will impact the results validity. (© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.) |
| References: | Cerebrovasc Dis. 2013;35(1):40-4. (PMID: 23428995) Int J Stroke. 2015 Oct;10(7):1115-8. (PMID: 25708372) Stroke. 2011 Apr;42(4):1158-92. (PMID: 21293023) N Engl J Med. 2010 Dec 23;363(26):2499-510. (PMID: 21128814) Eur J Neurol. 2017 Oct;24(10):1203-1213. (PMID: 28833980) Eur J Clin Pharmacol. 2005 Dec;61(12):873-80. (PMID: 16328318) Stroke. 2004 Mar;35(3):664-70. (PMID: 14976332) Neurol Neurochir Pol. 2019;53(5):384-387. (PMID: 31454061) N Engl J Med. 2005 Apr 28;352(17):1791-8. (PMID: 15858188) Curr Med Res Opin. 2018 Jul;34(7):1285-1292. (PMID: 29334815) Curr Med Res Opin. 2008 Oct;24(10):2757-65. (PMID: 18715524) Int J Stroke. 2015 Oct;10 Suppl A100:167-8. (PMID: 26502976) Stroke. 2014 Aug;45(8):2469-71. (PMID: 25070963) Lancet Neurol. 2007 Feb;6(2):162-70. (PMID: 17239803) Circulation. 2010 Jun 29;121(25):2740-6. (PMID: 20547928) J Thromb Haemost. 2005 Apr;3(4):692-4. (PMID: 15842354) N Engl J Med. 2008 Jun 26;358(26):2776-86. (PMID: 18579812) Clin Neurol Neurosurg. 2018 Dec;175:108-111. (PMID: 30396036) Expert Opin Pharmacother. 2008 Apr;9(5):677-86. (PMID: 18345947) Stroke. 2019 Feb;50(2):501-503. (PMID: 30621526) J Clin Pharmacol. 2005 Feb;45(2):127-32. (PMID: 15647404) Stroke. 2010 Sep;41(9):1901-6. (PMID: 20634477) Eur J Neurol. 2010 Oct;17(10):1229-35. (PMID: 20402748) JAMA Neurol. 2019 Dec 1;76(12):1457-1465. (PMID: 31479105) J Manag Care Pharm. 2006 Oct;12(8):640-8. (PMID: 17269842) N Engl J Med. 2011 Sep 8;365(10):883-91. (PMID: 21830957) Acta Med Indones. 2018 Oct;50(4):343-345. (PMID: 30631001) |
| فهرسة مساهمة: | Keywords: Rivaroxaban; anticoagulation; cerebral venous thrombosis; recanalization; vitamin K antagonist |
| تواريخ الأحداث: | Date Created: 20210104 Latest Revision: 20220419 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC7717856 |
| DOI: | 10.1080/21556660.2020.1838769 |
| PMID: | 33391859 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher 
Full Text Finder | تدمد: | 2155-6660 |
|---|---|
| DOI: | 10.1080/21556660.2020.1838769 |